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ABSTRACT
Purpose Linked maternity, neonatal and maternal mental 
health records were created to support research into the 
early life origins of physical and mental health, in mothers 
and children. The Early Life Cross Linkage in Research 
(eLIXIR) Partnership was developed in 2018, generating 
a repository of real- time, pseudonymised, structured 
data derived from the electronic health record systems 
of two acute and one Mental Health Care National Health 
Service (NHS) Provider in South London. We present 
early descriptive data for the linkage database and the 
robust data security and governance structures, and 
describe the intended expansion of the database from its 
original development. Additionally, we report details of the 
accompanying eLIXIR Research Tissue Bank of maternal 
and neonatal blood samples.
Participants Descriptive data were generated from the 
eLIXIR database from 1 October 2018 to 30 June 2019. 
Over 17 000 electronic patient records were included.
Findings to date 10 207 women accessed antenatal care 
from the 2 NHS maternity services, with 8405 deliveries 
(8772 infants). This diverse, inner- city maternity service 
population was born in over 170 countries with an ethnic 
profile of 46.1% white, 19.1% black, 7.0% Asian, 4.1% 
mixed and 4.1% other. Of the 10 207 women, 11.6% 
had a clinical record in mental health services with 3.0% 
being treated during their pregnancy. This first data extract 
included 947 infants treated in the neonatal intensive 
care unit, of whom 19.1% were postnatal transfers from 
external healthcare providers.
Future plans Electronic health records provide potentially 
transformative information for life course research, 
integrating physical and mental health disorders and 
outcomes in routine clinical care. The eLIXIR database 
will grow by ~14 000 new maternity cases annually, 
in addition to providing child follow- up data. Additional 
datasets will supplement the current linkage from other 
local and national resources, including primary care and 
hospital inpatient data for mothers and their children.
INTRODUCTION
Investment in health in the earliest stages of 
life is increasingly recognised as a means to 
improve the life course of health; beginning 
in utero, through to infancy, childhood and 
into adulthood.1 2 Much of the supporting 
evidence underpinning a ‘life course 
approach’ to disease prevention from preg-
nancy and infancy onwards has been accrued 
from large birth cohorts3–6; however, directly 
recruited cohorts are by definition drawn 
from individuals recruited over a prespecified 
and limited time period and thereby become 
rapidly outdated as temporal shifts in popu-
lation demography, lifestyle and ethnicity 
occur. Moreover, facility- centred follow- up is 
expensive and difficult to sustain.7 8 Sample 
attrition is common and can introduce signif-
icant methodological biases that may affect 
the validity of investigations into novel risk 
outcomes.9 In addition, direct recruitment 
may result in cohorts with a limited repre-
sentation of the target population because 
of selective inclusion. Population- based regis-
tries also offer insight into rarer diseases and 
outcomes, not feasible in current research 
cohorts. Linked administrative data are 
Strengths and limitations of this study
 ► The Early Life Cross Linkage in Research (eLIXIR) is 
a unique population- based database incorporating 
clinical data from maternity, neonatal and mental 
health records enabling life course studies of phys-
ical and mental health in a large, diverse, inner- city, 
UK population.
 ► Studies undertaken using eLIXIR will have not only 
have implications for local healthcare improvement 
but also the potential to provide evidence to influ-
ence healthcare in similar national/global settings.
 ► Missingness and inaccuracy in all routine/adminis-
trative clinical databases will be a key limitation to 
this database.
 ► The representativeness of the cohort to the UK pop-
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increasingly used to provide evidence to guide policy and 
clinical management.10–12 The longitudinal nature of such 
case registers, their size and coverage of defined popula-
tions provide an increasingly attractive alternative to the 
study of birth cohorts for defining the early life exposures 
that contribute to the population burden of physical and 
mental health disorders. These can provide longitudinal 
information on large numbers of women and children, 
as well as the potential for linkage with a widening port-
folio of available local and national datasets to follow 
health from birth to adulthood (https:// digital. nhs. uk/ 
data- and- information/ data- collections- and- data- sets/ 
data- sets). Both inclusion and attrition bias of traditional 
birth cohorts can be overcome through routine compre-
hensive health records, as these can capture rich clinical 
data in a given population on all women receiving ante-
natal care and their infants.13 Although well established 
in Scandinavian countries, national birth registries in the 
UK have not been widely used in linkage programmes 
using infant and childhood data, although population 
registry data from Scotland have for many years provided 
information on relationships between maternal and 
neonatal outcomes that has informed clinical guide-
lines in the UK and beyond.14 Several linkages of clinical 
maternity and infant data have nonetheless shown the 
feasibility of the approach and usefulness, for example, 
in aligning hospital maternity data with national birth 
registration datasets, or birth registration datasets with 
Hospital Episode Statistics (HES), or using UK primary 
care pregnancy data to create a pregnancy register.15–25
It is well established that maternal physical and mental 
well- being in pregnancy and the postpartum period can 
strongly influence the neonatal outcome and the phys-
ical and mental health of the child.26–29 To our knowl-
edge, no clinical data linkages in maternity or neonatal 
services have to date incorporated clinical information 
from maternity, neonatal and mental health services into 
a single continuum to interrogate these associations at a 
population level. The Early Life Cross Linkage in Research 
(eLIXIR) Partnership has been developed to address 
these relationships from early pregnancy, the perinatal 
period and beyond into later life. Funded by the Medical 
Research Council (MRC) in 2017, the partnership is a 
multidisciplinary academic collaboration that aims to 
combine maternal, infant and child health data into a 
single resource to allow information from large numbers 
of mothers, babies and children to be investigated over 
an unlimited time period. The intention is to provide a 
naturally accumulating database to support investigations 
into associations between physical and mental health in 
mother and child.
The eLIXIR Partnership provides a mechanism through 
which research datasets can be linked to clinical records, 
under appropriate and approved levels of anonymity and 
data security. An added benefit is the potential to incor-
porate data from multiple sources, for example, health, 
environment, social and education. There are, however, 
important ethical and legal considerations, as well as 
technical security requirements, if linkages are to be 
performed between sources of routinely collected clin-
ical data and exemption from individual consent to be 
permissible.30
Another aspect of the eLIXIR Partnership is the eLIXIR 
Research Tissue Bank established to link the routinely 
collected maternal and neonatal clinical data with biolog-
ical samples. This has an advantage over static cohort 
studies by providing a ‘dynamic’ collection of samples, 
enabling the identification of population trends and 
influences of new clinical interventions. The provision of 
samples from women attending antenatal care will provide 
a unique biobank to address mechanisms of common and 
rarer complications in pregnancy and in neonatal life, 
and their consequences for the longer- term health of the 
mother and child. Common complications will include 
gestational diabetes, mental illness, prematurity and pre- 
eclampsia. Similarly, by the provision of samples from 
neonatal intensive care, eLIXIR will contribute to a better 
understanding of neonatal morbidity and mortality.
With records of over 14 000 individual births per year, 
eLIXIR has the potential to become one of the largest 
mother–infant–child datasets in Europe. This has 
been facilitated by King’s Health Partners (KHP): an 
Academic Health Sciences Centre that brings together 
one academic institution (King’s College London) and 
three National Health Service (NHS) Foundation Trusts 
(Guys and St Thomas’ NHS Foundation Trust (GSTT), 
King’s College Hospital NHS Foundation Trust (KCH) 
and South London and Maudsley NHS Foundation Trust 
(SLaM)).
This manuscript details the technical and procedural 
elements in place to safeguard the legal and ethical rights 
of service users during the development and use of the 
eLIXIR database and to present the demographic profile 
of the eLIXIR population. Both technical and proce-
dural elements draw strongly on experience gained in 
setting up the Clinical Record Interactive Search (CRIS) 
data resource at the Maudsley National Institute for 
Health Research (NIHR) Biomedical Research Centre 
(BRC).31–33
Benefits of the system
Large data- linkage platforms, such as that created by the 
eLIXIR Partnership, provide a unique data warehouse 
through which important epidemiological questions 
can be asked, in the case of eLIXIR, within a large and 
diverse inner- city population. The ability to conduct 
these linkages allows not only the collection of a wide 
range of longitudinal health and social data, but also the 
capacity to support life course data analysis. The poten-
tial benefits arising from the use of clinical record ‘big 
data’ have been widely reported, and research databases 
such as eLIXIR are likely to increase in number due to 
the powerful and cost- effective nature of this research 
method.34 35 eLIXIR is one of the first longitudinal 
research databases, from early pregnancy onwards, using 
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Maternity and neonatal data were obtained from GSTT 
and KCH, and mental health data from SLaM. GSTT 
provides a full range of hospital and community services 
for people in Lambeth, Southwark and Lewisham, as well 
as specialist care for patients from further afield including 
referrals for high- risk pregnancies and neonatal compli-
cations. Similarly, KCH serves the boroughs of Lambeth, 
Southwark and Lewisham, but also Bromley, with 
specialist services to patients across a wider catchment 
area, including referrals for obstetrics and fetal medicine. 
SLaM provides comprehensive mental health services 
to a geographic catchment of over 1.2 million residents 
in four south London boroughs, Croydon, Lambeth, 
Lewisham and Southwark, as well as some regional/
national specialist mental health services.
Maternity, birth and neonatal intensive care data
The BadgerNet Platform (CleverMed) for routine clinical 
data is used extensively across the UK to create electronic 
patient records that capture early pregnancy community- 
based events and hospital- based events for low- risk and 
high- risk pathways of care (BadgerNet Maternity), and 
neonatal intensive care, neonatal transport, paediatric 
intensive care, neurology referrals and adult intensive 
care data (BadgerNet Neonatal). Within GSTT and 
KCH, the BadgerNet platforms are used for recording 
maternal/infant personal data, demographics, clinical 
history, clinic data (maternity only) and hospital episode 
data. The BadgerNet System records clinical records on a 
Single Care Record system, which is nationally hosted.36 
Although feasible within the BadgerNet System, linkage 
between maternity and neonatal data is not routinely 
conducted.
Mental health data
Clinical records have been fully electronic across all SLaM 
NHS Trust mental health services since April 2006, using 
the bespoke electronic Patient Journey System (ePJS) 
that incorporated legacy data from earlier service- specific 
electronic health records. The CRIS platform33 was 
developed in 2007–2008 and consists of a series of data- 
processing pipelines that both structure and de- identify 
PJS fields, rendering pseudonymiseddata from the full 
clinical record available at the researcher interface, with 
search and database assembly functionality facilitated by a 
front end, designed for non- technical use. The de- identi-
fying process and its effectiveness, including the masking 
of identifying information in open- text fields and the 
generation of a pseudonymised identifier (CRIS ID), 
have been previously described.32 The wider patient- led 
oversight and security models for CRIS have not changed 
significantly since it was established.31–33 Ethical approval 
was obtained for CRIS as a pseudonymised database for 
secondary analysis (Oxford C Research Ethics Committee, 
reference 18/SC/0372). In terms of cohort coverage, all 
SLaM care (including diagnoses, medication and services 
provided) is represented on CRIS, including Improving 
Access to Psychological Therapies data (IAPT; a large 
primary care service providing short- term psychological 
therapies).
Data-linkage hosting environment
Data for eLIXIR are managed and stored at the Clin-
ical Data- Linkage Service (CDLS) at SLaM: an impartial 
trusted third- party service that provides researchers access 
to linked clinical data in accordance with the strict gover-
nance conditions and processes agreed with relevant data 
controllers. The CDLS is managed by a small, dedicated 
team of informaticians, IT and Information Governance 
(IG) professionals (https://www. maudsleybrc. nihr. ac. 
uk/ facilities/ clinical- record- interactive- search- cris/), 
and currently hosts a range of datasets already linked 
with the SLaM CRIS mental health case register (eg, 
HES, National Cancer Registry, ONS death certification, 
Lambeth DataNet primary care records and National 
Pupil Database). The backbone of the eLIXIR database 
consists of a ‘master patient index’ (figure 1) allowing 
data to be robustly linked within an appropriately secure 
environment according to data specifications.
The CDLS hosts both source data and the master patient 
index, on behalf of the eLIXIR Partnership, on a secure 
server within the NHS firewall with role- restricted access. 
The CDLS additionally provides a data extraction service 
that meets security requirements, creating bespoke data-
sets for approved research use. Such derived data are 
managed by the approved research team and are hosted 
at all times on a dedicated drive within the NHS for anal-
ysis in this domain using hosted software already available 
at SLaM.
Four distinct services are offered by the CDLS as the 
data processor for the eLIXIR data. First, CDLS provides 
advice on permissions, approvals and contracts. These 
include the consideration of academic, technical, legal 
and ethical requirements. Second, CDLS facilitates data 
linkages either within the CDLS safe haven or via a third 
party, coordinating the secure transfer of data. Third, the 
CDLS is responsible for the secure storage of linked data 
in accordance with predefined IG and security standards. 
Fourth, the CDLS, as the custodian for the linked data, 
prepares and extracts bespoke and prespecified data-
bases for approved eLIXIR projects and provides these 
to researchers. Therefore, there is no direct access by 
researchers to the full linked data files, enhancing data 
protection and confidentiality.
Data-linkage procedures and resources
The eLIXIR Partnership uses common identifiers (eg, 
hospital number, NHS number, name and date of birth) 
to link between maternity, neonatal and mental health 
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researchers. Matching is undertaken using deterministic 
matching techniques on a given set of identifiers. Two 
records are said to match if all or some of the identifiers 
are identical, as defined by a hierarchical set of match- 
ranks. This creates a single master patient index including 
patient anonyms (mother and child), binary variables for 
presence/absence on each data source and key demo-
graphics. The source datasets and master patient index 
are stored by the CDLS behind the NHS firewall and 
linked data are extracted on a project- by- project basis by a 
CDLS informatician containing the variables and samples 
necessary for each study, with a study- specific encrypted 
anonym that contains completely pseudonymised data. 
In this way, databases are not stored in a linked format. 
The clinical data from maternity and neonatal services 
are extracted from BadgerNet Systems at both GSTT and 
KCH by information and communicaiton technology 
(ICT) staff at each site. These data are then sent securely 
to the staff at the SLaM CDLS and linked, using their 
common identifiers, with data from the CRIS system to 
incorporate mental health clinical data, where present, 
for each patient. This results in a comprehensive data 
resource to which researchers can apply for extracted 
data across maternity, neonatal and/or mental health 
services. Figure 1 details the dataflow for the eLIXIR 
Partnership database. Match quality is assured as 100% 
of infants born within the eLIXIR dataset were matched 
with their mothers’ records with the BadgerNet System.
IG framework
Results from linkages, current and prior, are stored within 
the CDLS safe haven, and the CDLS plays a key role in 
wider governance, supplementing the role of eLIXIR- 
specific oversight and data security, including the secure 
handling and storage of identifier fields required for data 
linkage. Section 251 (s251) of the NHS Act 2006 allows 
the common law duty of confidentiality to be set aside in 
specific circumstances where anonymised information 
is not sufficient and where ‘opt- in’ patient consent is not 
practical. Opt- out information and details of the project 
are given to each patient entering maternity and neonatal 
services and patients have the option of opting out of the 
programme at any time. Approval under this legal frame-
work was granted by the Health Research Authority (HRA) 
Confidentiality Advisory Group (CAG) to the eLIXIR team 
for all the above linkages, which allow data to be available in 
an identifiable format to a small number of data- processing 
staff in accordance with data sharing contracts between the 
data provider institutions (HRA CAG Ref: 18/CAG/0040). 
Therefore, for current and future data linkages within 
eLIXIR, ethical (REC) and s251 approval is required either 
through amendments to our existing agreements or new 
applications to these regulatory bodies. Activity for proj-
ects using linked datasets held by eLIXIR is audited by the 
eLIXIR Oversight Committee, helping to ensure that the 
researcher’s project requirements (eg, clinical research, 
surveillance, service improvement or audit) are met and 
that projects progress within the agreed policy and practice 
framework. The primary role of the Committee is to provide 
the operational management of eLIXIR as identified in 
the eLIXIR Security Model and protocol for the eLIXIR 
Research Tissue Bank. In so doing, the Committee seeks 
to promote the scientific and ethical principles that should 
govern the use of eLIXIR data and seeks to represent stake-
holders (who include the KHP Caldicott Guardians (indi-
viduals responsible for research governance at each NHS 
Trust site), service users, clinical professionals, lay persons 
and academics) and reflect their views and interests.
Public and patient involvement
Public and patient involvement (PPI) involvement was 
incorporated throughout the development of the eLIXIR 
Partnership. The concept of the eLIXIR Partnership was 
presented to a variety of PPI groups, including the Maud-
sley BRC Data Linkage Service User and Carer Advisory 
Group,37 Lambeth HealthWatch and the Young Persons 
Advisory Group at Great Ormond Street Hospital. PPI 
is ensured in the decision- making process of approving 
Figure 1 Data flow diagram for the eLIXIR partnership linkage. CDLS, Clinical Data- Linkage Service; eLIXIR, Early Life Cross 
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eLIXIR projects through lay member representation on 
the eLIXIR Oversight Committee. The eLIXIR Oversight 
Committee reviews and approves all projects using eLIXIR 
data.
Research Tissue Bank
The eLIXIR Research Tissue Bank is a prospective 
biobank of samples from pregnant women and infants 
being treated by GSTT. The Research Tissue Bank is 
integrated into the KCL Human Tissue Act (HTA) gover-
nance structure with active recruitment and collection 
of samples. All pregnant women aged over 16 years who 
are willing and able to give informed consent and infants 
admitted to the neonatal unit that have parental consent 
are eligible for inclusion in the eLIXIR Research Tissue 
Bank (Cambridge East Research Ethics Committee, refer-
ence 18/EE/0120).
Maternal blood sample collection
Eligible women are recruited at the time of routine 
antenatal care venepuncture (11–15 weeks’ gestation or 
later transfer of care or later antenatal care attendance) 
at GSTT. Women who agree to participate give written 
informed consent and an extra blood sample is collected 
at the same time as routine venepuncture, maximum 
volume 12 mL (2×6 mL tubes).
Infant blood sample collection
It is our intention also to recruit samples from infants 
admitted to the neonatal intensive care unit (NICU), 
when blood is drawn for routine tests. Following written 
informed parental consent, residual blood from routine 
samples, which otherwise would be discarded, will be 
retained and collected. The samples will be processed and 
stored in a similar manner to the maternal blood samples.
Following birth in the community setting (home visits), 
every infant, whose mother has provided consent, is offered 
new- born blood spot screening to exclude metabolic disor-
ders. A health professional pricks the baby’s heel to collect 
four drops of blood on a card. For the biobank, an extra 
card to those taken for clinical purposes is used to collect 
extra bloodspots from the infant, after the routine spots are 
collected using the same heel prick. This sample is posted 
back to the eLIXIR team and stored in the research labora-
tory prior to transfer to a central storage facility.
All samples are transferred for processing in the research 
laboratory. After processing, all tubes are labelled with a 
study- specific barcode and entered on to a study- specific 
database (FreezerPro). The samples are stored in −80°C 
freezers for short term, before being transported to a central 
storage facility (NIHR BioResource, Milton Keynes).
FINDINGS TO DATE
Maternal, birth and birth outcomes
From the first data extraction (1 October 2018–30 June 
2019) 10 207 women accessed antenatal care through 
GSTT or KCH maternity services with 8405 deliveries 
(8772 infants). This diverse, inner- city antenatal popu-
lation was born in over 170 countries with a heteroge-
neous distribution across ethnic groups (table 1). Most 
were born outside the UK but most reported English as 
their primary language. Women were booked on average 
at 11.6 weeks gestation, which is slightly higher than 
the national guidelines of before 10 weeks.38 The most 
common physical conditions experienced were; gynaeco-
logical problems (14%), asthma (8%) and pre- existing 
diabetes (6%). In addition, around one in five reported 
mental health problems, 3% were recorded as being 
exposed to female genital mutilation and 4% reported 
being current smokers at the time of their antenatal 
appointment (table 1).
With regard to birth episodes, twice as many women 
gave birth at GSTT than KCH with a mean gestational 
age at delivery of 38.8 weeks, and with 8% born prema-
turely (<37 completed weeks of gestation) and 3% born 
very prematurely (<34 weeks’ gestation). Of the 8405 
births, 8051 were singletons, 341 were twin births and 13 
were triplets. Around half of deliveries were spontaneous 
cephalic, around one in five were emergency (or unspec-
ified) caesarean section, and 15% elective caesarean 
section. Rates of stillbirth and neonatal deaths were 0.6% 
and 0.4%, respectively. The mean birth weight was 3257 g 
with 17% small for gestational age and 7% large for gesta-
tional age (table 2).
NICU admissions
Of the 947 infants that had been treated in NICUs across 
both GSTT and KCH, 19.1% were postnatal transfers 
from an external trust and 8.7% were in utero transfers. 
The main reason for admission was for respiratory disease 
(28%) followed by preterm birth (22%). The average 
length of time spent in the NICU was 15.8 days. Of 
outcomes following admission 46% were readmitted to a 
postnatal ward, 29% were discharged home and neonatal 
death occurred in 4%, the remainder being unknown 
from the data available (table 3).
Mental health
Of the 10 207 women attending antenatal care as regis-
tered in the eLIXIR database, 1184 had a clinical record 
in secondary mental health services (SLaM) with 307 
women actively being treated at the time of their preg-
nancy (201 under the care of IAPT) (table 4).
Research Tissue Bank
Following all necessary governance agreements samples 
were collected over a period of 3 months. A total of 1271 
aliquoted samples (including EDTA, serum and whole 
blood) from 123 women were stored in the FreezerPro 
system. In this period, 63.4% of women approached gave 
consent to take part.
Strengths and limitations
The eLIXIR Partnership has developed a unique 
population- based database incorporating clinical data 
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This is supplemented by the eLIXIR Research Tissue 
Bank. Together this resource will provide the basis for 
additional linkages to enable life course studies of phys-
ical and mental health in a large, diverse, inner- city, UK 
population. This will have not only implications for local 
healthcare improvement but also the potential to provide 
evidence to influence healthcare in similar national/
global settings.
A limitation common to all routine/administrative 
clinical databases is source data missingness and inac-
curacy. This, in contrast, is an advantage of prospective 
research cohorts. Nonetheless eLIXIR provides an oppor-
tunity for continuous feedback to the clinical provider on 
data absence or error. With regular meetings, we already 
appraise the Trust IT teams of, for example, dupli-
cate patient data entry and missing data, especially that 
required for the national Maternity Services Data Set. 
Thus, eLIXIR and other similar research datasets can 
contribute directly to improved clinical reporting, and 
hence to better clinical care.
Another potential limitation is the loss of data from 
women who move outside the catchment area within the 
index pregnancy and thereafter, although it is our inten-
tion to supplement the linkages with data from national 
HES to provide information on hospitalised outcomes. As 
with all administrative clinical datasets, research will be 
limited to that which can be conducted using information 
routinely collected in clinical care. The intended incor-
poration of research datasets offsets this to some extent. 
Additionally, clinical data entry may involve substantial 
human error and data may be absent from the clinical 
records (ie, missing). The representativeness of the 
cohort to the UK population is limited to mixed, inner- 
urban catchments. In addition, all three NHS Trusts 
involved in the eLIXIR Partnership incorporate special-
isms or local expertise attracting national- level referrals. 
As a result, data may be skewed to patients with more 
severe or complex health issues.
There are several advantages, but also disadvantages, 
to using pseudonymised electronic cohorts versus more 
traditional consented cohorts (eg, Avon Longitudinal 
Study of Parents and Children or Born in Bradford 
(BiB)). The greatest advantage lies in the contempo-
rary reporting of a population compared with historical 
cohorts, and we are aware that BiB has embarked on a 
Table 1 Characteristics of women attending antenatal 
booking appointments at Guy’s & St. Thomas’ NHS 
Foundation trust (GSTT) and King’s College Hospital NHS 













  White 2560 (44.9) 2151 (47.7) 4711 (46.1)
  Black 862 (15.0) 1089 (24.3) 1951 (19.1)
  Asian 474 (8.3) 248 (5.6) 722 (7.0)
  Mixed 218 (3.8) 192 (4.3) 410 (4.1)
  Other 248 (4.4) 253 (5.6) 501 (4.9)
  Not recorded 1338 (23.4) 574 (12.7) 1912 (18.8)
Born in the UK, n (%) 2150 (37.7) 2358 (52.3) 4508 (44.1)
Primary language English, 
n (%)
3711 (65.1) 3474 (77.1) 7185 (70.4)




Parity, mean±SD 0.7±1.1 0.8±1.1 0.8±1.1
Gravida, mean±SD 2.2±1.5 2.4±1.6 2.3±1.6
Prior medical conditions, n (%)
  Haematological 
disorder
231 (4.1) 407 (9.0) 638 (6.3)
  Thrombosis 57 (1.0) 35 (0.8) 90 (0.9)
  Cardiac disorders 103 (1.8) 103 (2.3) 206 (2.0)
  Hypertension 108 (2.0) 85 (1.9) 193 (1.9)
  Renal disorders 155 (2.8) 135 (3.0) 290 (2.9)
  Asthma 401 (7.0) 413 (9.3) 814 (8.0)
  Lung disorders 14 (0.2) 10 (0.3) 24 (0.2)
  Diabetes 375 (6.6) 257 (5.7) 627 (6.2)
  Endocrine disorders 307 (5.4) 205 (4.6) 512 (5.1)
  Autoimmune disorders 83 (1.4) 62 (1.4) 145 (1.4)
  Epilepsy 43 (0.7) 37 (0.8) 80 (0.8)
  Neurological disorders 146 (2.6) 355 (7.9) 501 (5.0)
  Gastrointestinal 
disorders
265 (4.6) 282 (6.2) 547 (5.4)
  Gynaecological 
disorders
742 (13.0) 673 (15.0) 1415 (14.1)
  Liver disorders 46 (0.9) 55 (1.2) 101 (1.0)
  Bone disorders 38 (0.7) 59 (1.4) 97 (0.9)
  Joint disorders 98 (1.7) 77 (1.7) 175 (1.8)
  Back problems 173 (3.0) 375 (8.4) 548 (5.1)
  Genetic disorders ND* ND* ND*
  Congenital 
abnormalities
29 (0.5) 27 (0.7) 56 (0.5)
  Other 85 (1.5) 121 (2.6) 206 (2.0)
Mental health problems 
(current or historical; self- 
reported), n (%)









Victim of female genital 
mutilation, n (%yes)
209 (3.7) 137 (3.0) 346 (3.4)
Smoker at booking, n 
(%yes)
195 (3.4) 199 (4.4) 394 (3.9)
*Not disclosed (ND). Actual numbers suppressed to reduce risk of 
statistical disclosure.
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mother–child linkage involving all mothers who consent 
to provide their pseudonymised routine data and that 
of their infants (eg, BiB 2019;  borninbradford. nhs. uk/ 
what- we- do/ pregnancy- early- years/ born- in- bradford). 
This and other planned ‘local’ UK linkages provide an 
opportunity for collaboration through meta- analysis to 
compare and contrast with other diverse UK populations. 
Another key advantage of pseudonymised records is the 
increased representativeness of under- represented groups 
of patients, often missing from traditional cohorts. Also, 
this approach avoids the cost implications of consent and 
cohort maintenance. However, traditional cohorts have 
Table 2 Characteristics of births and birth outcomes at 
Guy’s & St. Thomas’ NHS Foundation trust (GSTT) and 
King’s College Hospital NHS Foundation Trust (KCH) 









Very premature (<34 
weeks), n (%)




295 (5.2) 117 (4.3) 412 (4.9)
Term (>37 weeks), 
n (%)
5209 (91.4) 2708 (92.3) 7709 (91.7)
No of infants born, (no of pregnancies), n (%)
  Singleton 5459 (95.8) 2592 (95.7) 8051 (95.8)
  Twins 227 (4.0) 114 (4.2) 341 (4.1)
  Triplets ND* ND* 13 (0.2)
Type of delivery, n (%)
  Breech 32 (0.6) 16 (0.6) 48 (0.6)
  Elective 
caesarean 
section
862 (15.1) 412 (15.2) 1274 (15.2)




1132 (19.9) 461 (17.0) 1593 (19.0)
  Forceps 462 (8.1) 180 (6.6) 642 (7.6)
  Spontaneous 
cephalic
2838 (49.8) 1378 (50.9) 4216 (50.2)
  Ventouse 371 (6.5) 257 (9.5) 628 (7.5)
Birth outcome, n (%)
  Live birth 5644 (99.1) 2680 (99.0) 8324 (99.0)
  Stillbirth or 
neonatal death
53 (0.9) 28 (1.0) 81 (1.0)
Birth weight (grams) 3249.1±621.7 3273.3±621.25 3256.9±621.6
Small for 
gestational age 
(birth centile ≤10th), 
n (%)
551 (9.7) 259 (9.6) 810 (9.7)
Large for 
gestational age 
(birth centile ≥90th), 
n (%)
551 (6.6) 172 (6.4) 549 (6.6)
*Not disclosed (ND). Actual numbers suppressed to reduce risk of 
statistical disclosure.
Table 3 Characteristics of patients admitted to neonatal 
intensive care unit (NICU) at Guy’s & St. Thomas’ NHS 
Foundation trust (GSTT) and King’s College Hospital NHS 
Foundation Trust (KCH) between 1 October 2018 and 30 
June 2019
GSTT 
(n=645) KCH (n=302) Total (n=947)
Gestational age (weeks) 35.2 (±5.0) 35.7 (±4.6) 35.3 (±4.9)






No days on neonatal unit 15.3±24.7 16.9 (±26.2) 15.8 (±25.2)
No of episodes of care, n (%)
  1 476 (73.8) 254 (84.1) 730 (77.1)
  2 135 (20.9) 39 (12.9) 174 (18.4)
  3 ND* ND* 30 (3.2)
  4+ ND* ND* 13 (1.2)
Readmission (yes), n (%) 25 (3.9) 11 (3.6) 36 (3.8)
Consanguineous parents ND* ND* 11 (1.2)
Reason for admission, n (%)
  Preterm birth 132 (20.5) 73 (24.2) 205 (21.6)
  Respiratory disease 172 (26.7) 90 (29.8) 262 (27.6)
  Cardiovascular 
disease
*ND *ND 93 (9.8)
  Infection 11 (1.7) 12 (4.0) 23 (2.4)
  Jaundice 29 (4.5) 11 (3.6) 40 (4.2)
  Poor feeding/weight 
loss
ND* ND* 21 (2.2)
  Gastrointestinal 
disease
ND* ND* 24 (2.5)
  Hypoglycaemia 34 (5.3) 13 (4.3) 47 (5.0)
  Convulsions or 
neurological disease
ND* ND* 12 (1.3)
  Congenital 
abnormality
ND* ND* 28 (2.3)
  Surgery 67 (10.4) 27 (8.9) 94 (9.9)
  Investigation/
monitoring
26 (4.0) 14 (4.6) 40 (4.3)
  Poor condition at birth ND* ND* 22 (2.3)
  Other 19 (2.9) 17 (5.6) 36 (3.8)
  Maternal drug use ND* ND* 13 (1.4)
  Maternal smoking (n) 23 (3.6) 20 (6.6) 43 (4.5)
Neonatal outcome, n (%)
  Ward 281 (43.6) 152 (50.3) 433 (45.7)
  Home 181 (28.1) 97 (32.1) 278 (29.4)
  Died 27 (4.2) 13 (4.3) 40 (4.2)
  Unknown 156 (24.2) 40 (13.2) 196 (20.7)
*Not disclosed (ND). Actual numbers suppressed to reduce risk of 
statistical disclosure.
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the advantage of much greater depth of biological and 
psychological information derived from procedures and 
validated questionnaires.
Plans for the future
As the eLIXIR database develops, expansions will incor-
porate health and social care data. The next phase of 
linkage will comprise a local primary care data resource, 
Lambeth DataNet (https:// selondonccg. nhs. uk/ in- your- 
area/ lambeth/ our- local- plans/), for which all necessary 
approvals are in place. Beyond- catchment hospitalisation 
data could be usefully captured by linkage to national data 
sources, for example, HES, as mentioned, which has been 
incorporated in the CRIS platform.33 Subject to approval, 
later linkages will incorporate prescribing and education 
data, in addition to a broader range of local healthcare 
information as eLIXIR infants enter age ranges covered by 
other specialties. Finally, the replication of this data- linkage 
model in other geographical settings in the UK would offer 
the potential to develop a national data network allowing 
both larger research cohorts and cross- site replication.
COLLABORATION
We have established a research database of mater-
nity, neonatal and mental health clinical data not only 
combining maternal physical and mental health clinical 
data during pregnancy and later neonatal health, but also 
providing added value through the potential for the addi-
tion of biological measurements (ie, omics data) from the 
eLIXIR Tissue Bank samples. The eLIXIR Programme has 
the capacity to continue to grow and develop exponentially, 
through internal and external collaborations, with small 
levels of attrition to follow- up and the ability to be used for 
both common and rare research outcomes. Furthermore, 
unlike comparable research programmes, the population 
we sample from is diverse on both ethnicity and sociode-
mographic levels providing richness of data, which has the 
potential to lead to exciting research findings.
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and King’s College Hospital (KCH) NHS Foundation Trust 









Ever received treatment from 
SLaM
658 (11.5) 526 (11.7) 1184 (11.6)
Under SLaM Care during 
pregnancy
180 (3.2) 127 (2.8) 307 (3.0)
Received psychological 
therapy (through IAPT) in 
pregnancy from SLaM
113 (2.0) 88 (2.0) 201 (2.0)
IAPT, Improving Access to Psychological Therapy; NHS, National 
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